Optiver Holding
VRDN icon

Optiver Holding’s Viridian Therapeutics VRDN Stock Holding History

Optiver Holding’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.26K Sell
218
-76
-26% -$2.26K ﹤0.01% 1489
2025
Q4 		$9.15K Sell
294
-282
-49% -$7.73K ﹤0.01% 1163
2025
Q3 		$12.4K Buy
+576
New +$10.4K ﹤0.01% 1167

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Optiver Holding's VRDN Position: Q1 2026 in Review

Optiver Holding reduced its Viridian Therapeutics (VRDN) stake by 26% in Q1 2026, selling an estimated $2.26K and leaving 218 shares worth $4.26K. The position accounts for ﹤0.01% of the portfolio, ranked #1489.

Optiver Holding first reported a position in VRDN in Q3 2025 and has held it in 3 quarters since. The position peaked at $12.4K in Q3 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Optiver Holding held 218 shares of Viridian Therapeutics worth $4.26K as of Q1 2026.
  • Optiver Holding sold 76 Viridian Therapeutics shares in Q1 2026, an estimated $2.26K.
  • Viridian Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1489 holding.
  • Optiver Holding first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's Viridian Therapeutics position peaked at $12.4K in Q3 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.